John Overdeck’s Iovance Biotherapeutics IOVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $79.1M | Buy |
19,010,697
+5,323,264
| +39% | +$20.2M | 0.06% | 392 |
|
|
2026
Q1 | $48M | Buy |
13,687,433
+9,289,444
| +211% | +$29.7M | 0.04% | 518 |
|
|
2025
Q4 | $12M | Buy |
4,397,989
+1,657,135
| +60% | +$3.83M | 0.02% | 1006 |
|
|
2025
Q3 | $5.95M | Sell |
2,740,854
-1,892,597
| -41% | -$4.47M | 0.01% | 1319 |
|
|
2025
Q2 | $7.97M | Buy |
4,633,451
+4,236,457
| +1,067% | +$10.5M | 0.01% | 959 |
|
|
2025
Q1 | $1.32M | Buy |
+396,994
| New | +$2.05M | ﹤0.01% | 2007 |
|
|
2024
Q4 | – | Sell |
-92,368
| Closed | -$867K | – | 3343 |
|
|
2024
Q3 | $867K | Sell |
92,368
-682,415
| -88% | -$6.47M | ﹤0.01% | 2209 |
|
|
2024
Q2 | $6.21M | Buy |
+774,783
| New | +$8.3M | 0.01% | 911 |
|
|
2023
Q4 | – | Sell |
-227,000
| Closed | -$1.03M | – | 3249 |
|
|
2023
Q3 | $1.03M | Sell |
227,000
-1,304,053
| -85% | -$8.51M | ﹤0.01% | 1913 |
|
|
2023
Q2 | $10.8M | Sell |
1,531,053
-1,026,134
| -40% | -$7.34M | 0.03% | 608 |
|
|
2023
Q1 | $15.6M | Buy |
2,557,187
+1,663,254
| +186% | +$11.5M | 0.04% | 439 |
|
|
2022
Q4 | $5.71M | Sell |
893,933
-517,225
| -37% | -$4.04M | 0.02% | 797 |
|
|
2022
Q3 | $13.5M | Buy |
1,411,158
+877,558
| +164% | +$10.1M | 0.05% | 407 |
|
|
2022
Q2 | $5.89M | Buy |
533,600
+408,700
| +327% | +$5.36M | 0.02% | 697 |
|
|
2022
Q1 | $2.08M | Sell |
124,900
-256,981
| -67% | -$3.97M | 0.01% | 1337 |
|
|
2021
Q4 | $7.29M | Buy |
381,881
+122,951
| +47% | +$2.71M | 0.02% | 972 |
|
|
2021
Q3 | $6.38M | Buy |
+258,930
| New | +$6.1M | 0.01% | 1048 |
|
|
2021
Q2 | – | Sell |
-170,300
| Closed | -$5.39M | – | 4293 |
|
|
2021
Q1 | $5.39M | Sell |
170,300
-136,862
| -45% | -$5.67M | 0.01% | 994 |
|
|
2020
Q4 | $14.3M | Buy |
307,162
+296,426
| +2,761% | +$11.8M | 0.04% | 475 |
|
|
2020
Q3 | $353K | Sell |
10,736
-77,873
| -88% | -$2.39M | ﹤0.01% | 2483 |
|
|
2020
Q2 | $2.43M | Buy |
+88,609
| New | +$2.91M | 0.01% | 998 |
|
|
2020
Q1 | – | Sell |
-189,327
| Closed | -$5.24M | – | 3452 |
|
|
2019
Q4 | $5.24M | Sell |
189,327
-312,443
| -62% | -$7.11M | 0.02% | 922 |
|
|
2019
Q3 | $9.13M | Buy |
+501,770
| New | +$11.1M | 0.03% | 583 |
|
|
2019
Q2 | – | Sell |
-149,841
| Closed | -$1.43M | – | 3486 |
|
|
2019
Q1 | $1.43M | Sell |
149,841
-201,691
| -57% | -$1.96M | ﹤0.01% | 1611 |
|
|
2018
Q4 | $3.11M | Buy |
+351,532
| New | +$3.39M | 0.01% | 1024 |
|
|
2018
Q3 | – | Sell |
-263,475
| Closed | -$3.37M | – | 3384 |
|
|
2018
Q2 | $3.37M | Buy |
263,475
+249,075
| +1,730% | +$3.64M | 0.01% | 1267 |
|
|
2018
Q1 | $243K | Sell |
14,400
-13,894
| -49% | -$210K | ﹤0.01% | 2882 |
|
|
2017
Q4 | $226K | Buy |
+28,294
| New | +$227K | ﹤0.01% | 2868 |
|
Other funds holding IOVA
MFM
PAI
John Overdeck's IOVA Position: Q2 2026 in Review
John Overdeck increased its Iovance Biotherapeutics (IOVA) stake by 39% in Q2 2026, buying an estimated $20.2M and bringing the position to 19,010,697 shares worth $79.1M. The position accounts for 0.06% of the portfolio, ranked #392.
John Overdeck first reported a position in IOVA in Q4 2017 and has held it in 28 quarters since. 289 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.
- John Overdeck held 19,010,697 shares of Iovance Biotherapeutics worth $79.1M as of Q2 2026.
- John Overdeck bought 5,323,264 Iovance Biotherapeutics shares in Q2 2026, an estimated $20.2M.
- Iovance Biotherapeutics made up 0.06% of John Overdeck's portfolio in Q2 2026, its #392 holding.
- John Overdeck first reported a position in Iovance Biotherapeutics in Q4 2017 and has held it in 28 quarters since.
- 289 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.
Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.